Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Cash & Equivalents (2016 - 2025)

Sanara MedTech (SMTI) has disclosed Cash & Equivalents for 15 consecutive years, with $14.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 8.22% year-over-year to $14.9 million, compared with a TTM value of $14.9 million through Sep 2025, down 8.22%, and an annual FY2024 reading of $15.9 million, up 208.48% over the prior year.
  • Cash & Equivalents was $14.9 million for Q3 2025 at Sanara MedTech, down from $17.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $27.3 million in Q1 2021 and bottomed at $2.8 million in Q1 2024.
  • Average Cash & Equivalents over 5 years is $13.6 million, with a median of $14.9 million recorded in 2025.
  • The sharpest move saw Cash & Equivalents soared 3996.23% in 2021, then tumbled 61.18% in 2024.
  • Year by year, Cash & Equivalents stood at $18.7 million in 2021, then plummeted by 51.97% to $9.0 million in 2022, then plummeted by 42.55% to $5.1 million in 2023, then skyrocketed by 208.48% to $15.9 million in 2024, then dropped by 5.91% to $14.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for SMTI at $14.9 million in Q3 2025, $17.0 million in Q2 2025, and $20.7 million in Q1 2025.